» Articles » PMID: 7795497

The Severity of Dependence Scale (SDS): Psychometric Properties of the SDS in English and Australian Samples of Heroin, Cocaine and Amphetamine Users

Overview
Journal Addiction
Specialty Psychiatry
Date 1995 May 1
PMID 7795497
Citations 331
Authors
Affiliations
Soon will be listed here.
Abstract

The Severity of Dependence Scale (SDS) was devised to provide a short, easily administered scale which can be used to measure the degree of dependence experienced by users of different types of drugs. The SDS contains five items, all of which are explicitly concerned with psychological components of dependence. These items are specifically concerned with impaired control over drug taking and with preoccupation and anxieties about drug use. The SDS was given to five samples of drug users in London and Sydney. The samples comprised users of heroin and users of cocaine in London, and users of amphetamines and methadone maintenance patients in Sydney. The SDS satisfies a number of criteria which indicate its suitability as a measure of dependence. All SDS items load significantly with a single factor, and the total SDS score was extremely highly correlated with the single factor score. The SDS score is related to behavioural patterns of drug taking that are, in themselves, indicators of dependence, such as dose, frequency of use, duration of use, daily use and degree of contact with other drug users; it also shows criterion validity in that drug users who have sought treatment at specialist and non-specialist agencies for drug problems have higher SDS scores than non-treatment samples. The psychometric properties of the scale were good in all five samples, despite being applied to primary users of different classes of drug, using different recruitment procedures in different cities in different countries.

Citing Articles

Neuropsychological Instruments and Tasks for Dependence Behaviors in Medication-Overuse Headache.

Lau C, Wang Y Curr Pain Headache Rep. 2025; 29(1):54.

PMID: 39985631 DOI: 10.1007/s11916-024-01334-3.


Determining the diagnostic cut-off on the Chinese version of severity of dependence scale for cannabis.

Chung A, Tse C Front Psychiatry. 2025; 15():1495119.

PMID: 39839131 PMC: 11747374. DOI: 10.3389/fpsyt.2024.1495119.


Validity, reliability and clinical utility of ASSIST-Y in assessing risk of substance-related harm and dependence in Spanish male adolescents.

Ibanez-Martinez N, Stevens M, Civit-Bel N, Moreno-Ferrer N, Lopez-Ferre S, Olivares-Casado A Child Adolesc Psychiatry Ment Health. 2025; 19(1):1.

PMID: 39806480 PMC: 11731557. DOI: 10.1186/s13034-024-00845-6.


The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis.

Bortoletto R, Garzitto M, Piscitelli F, Fornasaro S, Scipioni C, Sepulcri O Brain Sci. 2025; 14(12.

PMID: 39766429 PMC: 11727594. DOI: 10.3390/brainsci14121230.


Pain Catastrophizing and Substance Misuse: A Scoping Review of the Literature.

Bichon J, Bailey A, Ford S, Lesser V, McHugh R Harv Rev Psychiatry. 2025; 33(1):8-30.

PMID: 39761442 PMC: 11881806. DOI: 10.1097/HRP.0000000000000415.